Analysts Set CryoPort, Inc. (NASDAQ:CYRX) Price Target at $14.44

CryoPort, Inc. (NASDAQ:CYRX) has been given an average rating of “Moderate Buy” by the nine research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $14.4375.

Several equities analysts recently commented on CYRX shares. BTIG Research increased their target price on shares of CryoPort from $15.00 to $17.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Guggenheim upped their price target on shares of CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Needham & Company LLC raised their price objective on CryoPort from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. Craig Hallum assumed coverage on CryoPort in a report on Monday, March 30th. They issued a “buy” rating and a $15.00 price objective on the stock. Finally, Wall Street Zen raised CryoPort from a “sell” rating to a “hold” rating in a research note on Monday, May 11th.

CryoPort Trading Up 1.3%

CYRX stock opened at $13.31 on Tuesday. The company’s 50 day moving average is $9.84 and its 200 day moving average is $9.52. The stock has a market cap of $670.82 million, a price-to-earnings ratio of 9.86 and a beta of 1.75. CryoPort has a 1-year low of $5.31 and a 1-year high of $13.79.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). The business had revenue of $47.80 million for the quarter, compared to the consensus estimate of $44.86 million. CryoPort had a net margin of 41.57% and a negative return on equity of 7.92%. As a group, sell-side analysts forecast that CryoPort will post -0.74 EPS for the current fiscal year.

Insider Activity

In other news, insider Mark W. Sawicki sold 3,235 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $8.00, for a total value of $25,880.00. Following the completion of the sale, the insider owned 103,697 shares of the company’s stock, valued at approximately $829,576. The trade was a 3.03% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Jerrell Shelton sold 7,918 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $8.00, for a total value of $63,344.00. Following the sale, the chief executive officer directly owned 1,054,501 shares of the company’s stock, valued at approximately $8,436,008. This trade represents a 0.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 59,939 shares of company stock valued at $471,183. Insiders own 10.10% of the company’s stock.

Institutional Trading of CryoPort

A number of institutional investors have recently made changes to their positions in CYRX. Basepoint Wealth LLC purchased a new stake in shares of CryoPort during the fourth quarter valued at approximately $34,000. Tower Research Capital LLC TRC boosted its stake in shares of CryoPort by 300.1% during the second quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock valued at $44,000 after purchasing an additional 4,375 shares during the period. Whittier Trust Co. of Nevada Inc. purchased a new stake in shares of CryoPort during the third quarter valued at approximately $53,000. AlphaQuest LLC purchased a new stake in shares of CryoPort during the third quarter valued at approximately $79,000. Finally, Creative Planning purchased a new stake in shares of CryoPort during the second quarter valued at approximately $96,000. Hedge funds and other institutional investors own 92.90% of the company’s stock.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.